| Not Yet Recruiting | A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coron NCT07454889 | Novartis Pharmaceuticals | — |
| Recruiting | A Study of Zasocitinib in Adults With Hidradenitis Suppurativa NCT07244263 | Takeda | Phase 2 |
| Withdrawn | Efficacy and Tolerability of a Fractional Ablative Erbium Laser for Axillary Scarring for Hidradenitis Suppura NCT05470322 | Montefiore Medical Center | N/A |
| Not Yet Recruiting | LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in NCT07336641 | Fondazione ISIDE | — |
| Recruiting | A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidrad NCT07225569 | Sanofi | Phase 2 |
| Recruiting | Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated NCT07243782 | Novartis Pharmaceuticals | — |
| Recruiting | Real-world Secukinumab Outcomes in Canadian HS Patients NCT07282015 | Novartis Pharmaceuticals | — |
| Recruiting | A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red NCT07228390 | Pfizer | Phase 2 |
| Recruiting | Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa NCT07170917 | Sanofi | Phase 2 |
| Recruiting | A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With NCT06888193 | UCB Biopharma SRL | Phase 1 |
| Recruiting | Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis NCT07049575 | Incyte Corporation | Phase 1 |
| Recruiting | A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa NCT07077902 | Tulane University | Phase 2 |
| Recruiting | A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata NCT07136467 | AbbVie | — |
| Not Yet Recruiting | A Study of LAD191 in Adults With Hidradenitis Suppurativa NCT07151937 | Almirall, S.A. | Phase 2 |
| Withdrawn | Gentian Violet Treatment for Hidradenitis Suppurativa NCT04388163 | Wake Forest University Health Sciences | Phase 2 |
| Enrolling By Invitation | A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participan NCT07007637 | MoonLake Immunotherapeutics AG | Phase 3 |
| Recruiting | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa ( NCT06959225 | Incyte Corporation | Phase 3 |
| Recruiting | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa ( NCT06958211 | Incyte Corporation | Phase 3 |
| Active Not Recruiting | Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) NCT06956235 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients NCT05821478 | Institut Pasteur | Phase 3 |
| Recruiting | An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizum NCT06326476 | University of Alabama at Birmingham | EARLY_Phase 1 |
| Recruiting | A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to NCT06921850 | UCB Biopharma SRL | Phase 3 |
| Recruiting | A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients Wi NCT06840392 | Novartis Pharmaceuticals | Phase 3 |
| Recruiting | Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients. NCT06895499 | Shanghai Huaota Biopharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Init NCT06785675 | Novartis Pharmaceuticals | — |
| Recruiting | Aviclear for Hidradenitis Suppurativa (HS) NCT06801795 | University of Miami | N/A |
| Not Yet Recruiting | Pathophysiological Basis of Hidradenitis Suppurativa NCT06370052 | Clinical Hospital Center Rijeka | — |
| Recruiting | A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients Wi NCT06799000 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticar NCT06555328 | InflaRx GmbH | Phase 2 |
| Withdrawn | Botulinum Toxin-A for Hidradenitis Suppurativa NCT06237465 | Yale University | Phase 4 |
| Not Yet Recruiting | A Journey Into Participation Patterns Among Patients With Hidradenitis Suppurativa NCT06201858 | Power Life Sciences Inc. | — |
| Recruiting | An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolesc NCT06768671 | MoonLake Immunotherapeutics AG | Phase 3 |
| Active Not Recruiting | A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa ( NCT06685835 | Insmed Incorporated | Phase 2 |
| Recruiting | A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moder NCT06707246 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Active Not Recruiting | Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa NCT06361836 | Sonoma Biotherapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic NCT06599411 | Assistance Publique - Hôpitaux de Paris | — |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppu NCT06603077 | Avalo Therapeutics, Inc. | Phase 2 |
| Recruiting | A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or NCT06524635 | AbbVie | Phase 2 |
| Active Not Recruiting | Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients Wit NCT06517732 | Novartis Pharmaceuticals | — |
| Recruiting | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderat NCT06468228 | AbbVie | Phase 3 |
| Active Not Recruiting | Anifrolumab for Hidradenitis Suppurativa NCT06374212 | University of North Carolina, Chapel Hill | Phase 2 |
| Active Not Recruiting | Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation NCT06444087 | Novartis Pharmaceuticals | — |
| Recruiting | A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers NCT06082323 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Partici NCT06411899 | MoonLake Immunotherapeutics AG | Phase 3 |
| Active Not Recruiting | Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participa NCT06411379 | MoonLake Immunotherapeutics AG | Phase 3 |
| Unknown | Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa NCT06301256 | Florida Academic Centers Research and Education, LLC | N/A |
| Completed | Development and EValuation of an Online Intervention to Reduce Self-Stigma in People With Visible Chronic Skin NCT06324695 | Universitätsklinikum Hamburg-Eppendorf | N/A |
| Not Yet Recruiting | Study of the Immunomodulation in the Hidradenitis Suppurativa and Evaluation of a New Therapeutic Strategy NCT05208099 | Lille Catholic University | — |
| Terminated | Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS). NCT05997277 | Beth Israel Deaconess Medical Center | Phase 2 |
| Active Not Recruiting | A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa NCT06046729 | Eli Lilly and Company | Phase 2 |
| Recruiting | Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers NCT05994976 | Innovaderm Research Inc. | — |
| Completed | Mindfulness in Hidradenitis Suppurativa NCT06123429 | University of Arkansas | N/A |
| Recruiting | Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa NCT06058520 | University of Minnesota | EARLY_Phase 1 |
| Terminated | A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants W NCT06028230 | Sanofi | Phase 2 |
| Completed | Validation of the French Version of the Score on Quality of Life (HiSQOL) in Hidradenitis Suppurativa (QUALIVE NCT05986825 | University Hospital, Brest | — |
| Active Not Recruiting | Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinum NCT05921994 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | HIDRAdenitis Suppurativa and HEART Disease NCT05989945 | Herlev and Gentofte Hospital | — |
| Unknown | The Living With a Long-Term Condition Study NCT06072287 | King's College London | — |
| Terminated | Hidradenitis Suppurativa Study of Izokibep NCT05905783 | ACELYRIN Inc. | Phase 3 |
| Recruiting | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent P NCT05889182 | AbbVie | Phase 3 |
| Unknown | A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological NCT05084417 | OM1, Inc. | — |
| Recruiting | Physical Activity in Hidradenitis Suppurativa (HS) NCT06015438 | University of Miami | N/A |
| Completed | A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa NCT05849922 | Sanofi | Phase 2 |
| Recruiting | Determinants of Chronic Inflammatory Skin Disease Trajectories NCT05928169 | University Hospital Schleswig-Holstein | — |
| Completed | Mindfulness Training Hidradenitis Suppurativa (HS) NCT05642039 | University of Miami | N/A |
| Completed | Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativ NCT05819398 | Boehringer Ingelheim | Phase 2 / Phase 3 |
| Completed | The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Ada NCT05913817 | Jamp Pharma Corporation | — |
| Completed | Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativ NCT05635838 | Incyte Corporation | Phase 2 |
| Unknown | Fractional CO2 Laser Fenestration and Steroid Delivery in HS Lesions NCT05580029 | University of Southern California | EARLY_Phase 1 |
| Unknown | Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppur NCT05934825 | Andalusian Network for Design and Translation of Advanced Therapies | Phase 1 / Phase 2 |
| Recruiting | Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment NCT04414514 | Milton S. Hershey Medical Center | Phase 2 |
| Recruiting | Regulation of Inflammatory Genes in Hidradenitis Suppurativa NCT05507125 | University of Alabama at Birmingham | — |
| Unknown | A Randomized, Controlled Trial Comparing the Use of a Biodegradable Temporizing Matrix to Cadaver Skin in the NCT05477225 | Joseph M. Still Research Foundation, Inc. | Phase 4 |
| Completed | Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis Suppurativa NCT05663268 | Services Institute of Medical Sciences, Pakistan | EARLY_Phase 1 |
| Unknown | Control of Hidradenitis Suppurativa of the Underarms After Combination Deroofing and Laser NCT05484674 | University of Texas at Austin | N/A |
| Terminated | A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS) NCT05348681 | Aristea Therapeutics, Inc. | Phase 2 |
| Recruiting | Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa NCT05531747 | Assistance Publique - Hôpitaux de Paris | N/A |
| Recruiting | Botulinum Toxin Therapy in Hidradenitis Suppurativa NCT05403710 | University of Massachusetts, Worcester | — |
| Completed | Hidradenitis Suppurativa Phase 2b Study of Izokibep NCT05355805 | ACELYRIN Inc. | Phase 2 |
| Unknown | Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa NCT05020730 | Phoenicis Therapeutics | Phase 2 |
| Unknown | JAK-STAT Signaling Pathway in Pyoderma Gangrenosum NCT04792957 | Dokuz Eylul University | — |
| Completed | Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativ NCT05322473 | MoonLake Immunotherapeutics AG | Phase 2 |
| Completed | Wet-to-dry vs Petrolatum & Non-stick Dressings After Hidradenitis Suppurativa Surgery NCT05194969 | University of North Carolina, Chapel Hill | N/A |
| Terminated | Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa NCT04582669 | Montefiore Medical Center | Phase 4 |
| Recruiting | Myriad™ Augmented Soft Tissue Reconstruction Registry NCT05243966 | Aroa Biosurgery Limited | — |
| Completed | ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) NCT05216224 | Aclaris Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With NCT05139602 | AbbVie | Phase 2 |
| Completed | Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa NCT04989517 | Azora Therapeutics Australia Pty Ltd | Phase 1 |
| Recruiting | Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Init NCT05635266 | Sanguine Biosciences | — |
| Terminated | A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa NCT04988308 | Janssen Research & Development, LLC | Phase 2 |
| Completed | A Bioelectric Dressing for Post De-Roofing Treatment of HS NCT05057429 | University of Miami | N/A |
| Unknown | Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa NCT04982432 | Gregor Jemec | Phase 2 |
| Completed | Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa NCT05040698 | Holdsworth House Medical Practice | Phase 2 |
| Completed | A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibit NCT05286567 | Aarhus University Hospital | Phase 1 |
| Completed | A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Su NCT04876391 | Boehringer Ingelheim | Phase 2 |
| Completed | Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (H NCT05093855 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 2 |
| Completed | Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa NCT04979520 | Rockefeller University | EARLY_Phase 1 |
| Completed | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidr NCT04856930 | Vanda Pharmaceuticals | Phase 2 |
| Completed | Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (H NCT05103423 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1 / Phase 2 |
| Unknown | Bacteriophage Therapy for Difficult-to-treat Infections: the Implementation of a Multidisciplinary Phage Task NCT06368388 | Universitaire Ziekenhuizen KU Leuven | — |
| Active Not Recruiting | A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradeni NCT04901195 | UCB Biopharma SRL | Phase 3 |
| Completed | A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa NCT04762277 | Boehringer Ingelheim | Phase 2 |
| Withdrawn | Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa NCT04541550 | IntegoGen, LLC | Phase 1 |
| Completed | Relationships Among Inflammation, Physical and Mental Health in Subjects With Chronic Inflammatory Physical Di NCT05125458 | University of Campania Luigi Vanvitelli | — |
| Completed | LTX-109 as Treatment for Hidradenitis Suppurativa NCT04756336 | Pharma Holdings AS | Phase 1 / Phase 2 |
| Completed | Hidradenitis Suppurativa (HS) Tunneling Wounds NCT04648631 | University of Miami | N/A |
| Completed | A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Derm NCT04772885 | Kymera Therapeutics, Inc. | Phase 1 |
| Completed | Metformin for the Treatment of Hidradenitis Suppurativa (HS) NCT04649502 | K.R. van Straalen | Phase 3 |
| Unknown | Intralesional Diode Laser Treatment of Fistulas in Hidradenitis Suppurativa NCT04508374 | Zealand University Hospital | N/A |
| Completed | Tofacitinib for Immune Skin Conditions in Down Syndrome NCT04246372 | University of Colorado, Denver | Phase 2 |
| Completed | Evaluating the Effect of a Written Action Plan on Comfort and Understanding of Hidradenitis Suppurativa NCT04600375 | University of Arkansas | N/A |
| Recruiting | Defects of Keratinocytes Function in Dermatologic Patients NCT06324552 | IRCCS Burlo Garofolo | — |
| Withdrawn | Spironolactone for Hidradenitis Suppurativa NCT04100083 | Medical University of South Carolina | Phase 4 |
| Withdrawn | Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis S NCT03929835 | TO Pharmaceuticals | Phase 2 |
| Completed | A Study of LY3041658 in Adults With Hidradenitis Suppurativa NCT04493502 | Eli Lilly and Company | Phase 2 |
| Completed | To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa NCT04476043 | Incyte Corporation | Phase 2 |
| Withdrawn | Hidradenitis Suppurativa Patient Experience With Humira Treatment NCT04132388 | Wake Forest University Health Sciences | Phase 4 |
| Recruiting | Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository NCT04115566 | University of California, San Francisco | — |
| Withdrawn | Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab. NCT04084665 | Rockefeller University | EARLY_Phase 1 |
| Completed | Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic Dermati NCT04440410 | Kymera Therapeutics, Inc. | — |
| Completed | Therapeutic Effect of Methalazine on 27 Cases of Suppurative Hidradenitis NCT06568224 | The First Affiliated Hospital with Nanjing Medical University | — |
| Active Not Recruiting | Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Re NCT04179175 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidra NCT04242498 | UCB Biopharma SRL | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidra NCT04242446 | UCB Biopharma SRL | Phase 3 |
| Withdrawn | An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab NCT04249713 | Rockefeller University | EARLY_Phase 1 |
| Terminated | Hidradenitis Suppurativa Written Action Plan NCT04230291 | University of Arizona | N/A |
| Completed | Wound Dressings for Hidradenitis Suppurativa NCT04194541 | University of Miami | N/A |
| Recruiting | Battlefield Acupuncture for Pain in Hidradenitis Suppurativa NCT04218422 | Wayne State University | N/A |
| Unknown | Effectiveness of Interdisciplinary Care Compared to Usual Care in Patients With Immune-Mediated Inflammatory D NCT04200690 | University of Aarhus | N/A |
| Completed | Evaluating the Safety and Efficacy of Laight®-Therapy Treatment in Subjects With Hidradenitis Suppurativa NCT05927948 | Henry Ford Health System | N/A |
| Completed | HidraWear Study for Hidradenitis Suppurativa Wounds NCT04449354 | HidraMed Solutions Ltd | N/A |
| Completed | Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. NCT04061395 | University Medical Center Groningen | Phase 2 |
| Terminated | Hidradenitis - an Analysis of Genetic Traits and Linkages in Families NCT05710393 | University of Chicago | — |
| Completed | A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurat NCT04019041 | Janssen Research & Development, LLC | Phase 2 |
| Terminated | Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa NCT04325607 | Royal Free Hospital NHS Foundation Trust | N/A |
| Unknown | Safety and Efficacy of Laser Therapy in Gynaecology NCT04073082 | Juna d.o.o. | — |
| Completed | Complement C5a Receptors in Hidradenitis Suppurativa NCT04251663 | Stanford University | — |
| Completed | Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS NCT04018599 | Fresenius Kabi SwissBioSim GmbH | Phase 1 |
| Completed | Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplant NCT03972280 | CSL Behring | Phase 1 |
| Completed | A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Su NCT03926169 | AbbVie | Phase 2 |
| Completed | Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab NCT03960268 | Rockefeller University | EARLY_Phase 1 |
| Unknown | Treatment of Moderate Hidradenitis Suppurativa NCT03910803 | Florida Academic Dermatology Centers | Phase 2 |
| Active Not Recruiting | Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Su NCT03827798 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis NCT03713632 | Novartis Pharmaceuticals | Phase 3 |
| Completed | This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe H NCT03713619 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AU NCT03852472 | Amgen | Phase 2 |
| Active Not Recruiting | A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC NCT03661866 | Target PharmaSolutions, Inc. | — |
| Completed | A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa NCT03607487 | Incyte Corporation | Phase 2 |
| Completed | A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants Wit NCT03628924 | Janssen Research & Development, LLC | Phase 2 |
| Unknown | Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS NCT03221621 | Erasmus Medical Center | Phase 4 |
| Completed | A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa NCT03569371 | Incyte Corporation | Phase 2 |
| Completed | A Study of Bermekimab in Patients With Hidradenitis Suppurativa NCT03512275 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Hidradenitis Suppurativa Mail Survey NCT03572738 | Wake Forest University Health Sciences | — |
| Unknown | Hidradenitis Suppurativa and Periodontal Diseases NCT03553888 | CHU de Reims | — |
| Withdrawn | A Single Center, Prospective Clinical Trial of Intravenous Ertapenem in the Treatment of Hurley Stage II or II NCT05255575 | Henry Ford Health System | — |
| Terminated | Safety and Treatment of Cryoinsufflation in Treatment of Hidradenitis Suppurativa NCT05830149 | Henry Ford Health System | N/A |
| Completed | Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa NCT03275870 | Elena Gonzalez Brant, MD | Phase 1 / Phase 2 |
| Completed | A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe H NCT03248531 | UCB Biopharma SRL | Phase 2 |
| Terminated | Microwave Ablation in Mild Axillary Hidradenitis Suppurativa NCT03238469 | M.B.A. van Doorn | N/A |
| Recruiting | Feasibility Study on Radiofrequency-Based Selective Electrothermolysis to Investigate Its Effects on Human Ski NCT05066113 | Johns Hopkins University | N/A |
| Unknown | Intense Pulsed Light Therapy for Hidrosadenitis Suppurativa NCT03203122 | Zealand University Hospital | N/A |
| Terminated | Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Skin Conditions NCT03198390 | University of Arizona | — |
| Completed | Pilot Study on Botulinum Toxin B as Treatment for Hidradenitis Suppurativa NCT03103074 | University Hospital of North Norway | N/A |
| Completed | Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser NCT03054155 | Wayne State University | N/A |
| Recruiting | The Ohio State University Dermatology Biorepository NCT03146676 | Ohio State University | — |
| Terminated | Low Dose Radiotherapy for Advanced Hidradenitis Suppurativa NCT03040804 | Montefiore Medical Center | N/A |
| Completed | Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis NCT03049267 | M.B.A. van Doorn | Phase 2 |
| Completed | Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa NCT03001622 | InflaRx GmbH | Phase 2 |
| Completed | Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa NCT02904902 | AbbVie | Phase 3 |
| Completed | Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa NCT02805595 | Beth Israel Deaconess Medical Center | Phase 2 |
| Recruiting | Clinical and Biological Characteristics of Hidradenitis Suppurativa NCT03967600 | University of California, San Francisco | — |
| Completed | Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurat NCT03099980 | Tufts Medical Center | EARLY_Phase 1 |
| Completed | Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in NCT02786576 | AbbVie | — |
| Completed | Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa NCT02695212 | Florida Academic Dermatology Centers | Phase 2 |
| Completed | A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurati NCT02781818 | University of North Carolina, Chapel Hill | N/A |
| Completed | Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) P NCT02739828 | AbbVie | — |
| Completed | MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB NCT02643654 | Evangelos J. Giamarellos-Bourboulis, M.D. | Phase 2 |
| Completed | A National Registry For Patients With Hidradenitis Suppurativa NCT03289585 | Montefiore Medical Center | — |
| Completed | Nutritional Status and Hidradenitis Suppurativa (Acne Inversa) NCT03683238 | Federico II University | — |
| Completed | Impact of Hidradenitis Suppurativa on Quality of Life Functions NCT03288337 | Montefiore Medical Center | — |
| Completed | Quality of Life After Wide Surgical Excision in Patients With Hidradenitis Suppurativa NCT02593604 | University Hospital Schleswig-Holstein | — |
| Completed | Activation of a Cutaneous Inflammasome in the Skin of Hidradenitis Suppurativa Patients NCT02833909 | CHU de Reims | N/A |
| Completed | Study to Compare Two Treatments for Axillary Hidradenitis Suppurativa: Carbon Dioxide Laser Versus Surgical De NCT02163746 | Henry Ford Health System | N/A |
| Terminated | Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenit NCT01838499 | AstraZeneca | Phase 2 |
| Completed | Association Between Hidradenitis Suppurativa and Spondyloarthritis NCT03668925 | CHU de Reims | N/A |
| Completed | An Investigation Into the Efficacy of Provodine Topical Cream as Compared to 10% Benzoyl Peroxide Wash for the NCT01818167 | Henry Ford Health System | N/A |
| Completed | Anakinra as a Treatment for Hydradenitis Suppurativa NCT01516749 | University of California, San Francisco | Phase 2 |
| Completed | A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa NCT01704534 | University Medical Center Groningen | Phase 2 |
| Completed | Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa NCT01635764 | AbbVie (prior sponsor, Abbott) | Phase 3 |
| Completed | Anakinra in Hidradenitis Suppurativa NCT01558375 | University of Athens | Phase 2 |
| Completed | Wound Etiology and Healing Study NCT01352078 | George Washington University | — |
| Completed | Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa NCT01063270 | Henry Ford Health System | N/A |
| Completed | Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa NCT00918255 | Abbott | Phase 2 |
| Terminated | A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS NCT00722800 | Massachusetts General Hospital | Phase 2 |
| Completed | Study on the Effect of NdYag Laser for the Treatment of Hidradenitis Suppurativa NCT00494351 | Henry Ford Health System | N/A |
| Completed | To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa NCT00827996 | Florida Academic Dermatology Centers | Phase 2 |
| Completed | A Small Clinical Study: Photodynamic Therapy to Treat Hidradenitis Suppurativa NCT00395187 | University of Kansas | N/A |
| Completed | Etanercept in Hidradenitis Suppurativa NCT00329823 | University of Athens | Phase 2 |
| Completed | Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa NCT00795574 | Florida Academic Dermatology Centers | Phase 2 |
| Completed | Etanercept for Treatment of Hidradenitis NCT00107991 | University of Pennsylvania | Phase 2 |
| Completed | Treatment of Hidradenitis Suppurativa Using Etanercept NCT00949546 | Penn State University | — |
| Terminated | To Determine the Efficacy of a Laser Device for the Treatment of Hidradenitis Suppurativa NCT00367328 | University of California, Davis | Phase 3 |
| Completed | Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa NCT00134134 | NYU Langone Health | Phase 1 |